Medicare Part D Plans Required to Cap Insulin at $35 Per Month

For millions of Medicare beneficiaries managing diabetes, insulin isn't optional — it's a lifeline. For years, the cost of that lifeline was shockingly high: some seniors were paying hundreds of dollars every month just to stay alive. Starting January 1, 2026, that changed in a meaningful way.

As of that date, cost-sharing for all insulin products covered under a Medicare prescription drug plan (Part D coverage) is capped at $35 for a one-month supply. Critically, the Part D deductible does not apply to these covered insulin products — meaning the $35 cap kicks in immediately, without any waiting period.

This cap was introduced as part of the Inflation Reduction Act of 2022, and its impact on Medicare beneficiaries who depend on insulin is substantial.

How does the Inflation Reduction Act impact Medicare beneficiaries?

Before this legislation took effect, the financial burden of insulin was a genuine crisis for many seniors. The cost-sharing amounts on some insulin products pushed monthly expenses well beyond what many fixed-income beneficiaries could comfortably afford — and rationing insulin, or skipping doses to stretch a supply, was far more common than it should have been.

With the cap in place, Medicare beneficiaries on insulin will pay no more than $35 per month for each insulin product they use. That predictability alone represents a significant quality-of-life improvement for those who previously lived with the anxiety of fluctuating drug costs.

The relief is even more meaningful for beneficiaries who rely on multiple types of insulin — a common reality for people managing complex diabetes. In those cases, the cap applies per covered insulin product. Some seniors use both a long-acting and a rapid-acting insulin, and previously each came with its own cost-sharing amount. With the cap, $35 per product per month represents a ceiling, not a variable — and for beneficiaries who were paying far more, the savings can be substantial month after month.

Is this different from the Part D Senior Savings Model?

Yes — and the distinction matters. The Part D Senior Savings Model was a voluntary pilot program introduced by the Centers for Medicare and Medicaid Services (CMS) that offered a similar benefit: participating plans capped insulin copays at $35 per month beginning in 2021. The program ran through 2022 and involved a select group of participating Part D plans, along with three major pharmaceutical manufacturers — Eli Lilly and Company, Novo Nordisk, and Sanofi-Aventis — who agreed to test the impact of providing beneficiaries with more affordable insulin options.

The model was scheduled to sunset on December 31, 2026, superseded by the Inflation Reduction Act's mandate requiring all Part D plans — not just volunteers — to cap insulin costs. What was once a pilot for some beneficiaries is now a universal protection for all.

While CMS discontinued testing the model in subsequent calendar years, it acknowledges the program's meaningful contribution to the CMS Innovation Center's longer-term mission: building a healthcare system that achieves equitable outcomes through high-quality, affordable, person-centered care.

Conclusion

The $35 insulin cap is more than a policy change — it's a concrete step toward making healthcare financially sustainable for people who depend on insulin to manage a chronic condition. Unaffordable insulin doesn't just strain household budgets; it forces impossible choices that directly harm health. By capping these costs and eliminating the deductible barrier, the Inflation Reduction Act delivers real, immediate relief.

The Inflation Reduction Act has attracted support from patient advocacy organizations, healthcare providers, and policymakers across the spectrum — a reflection of how urgent the insulin affordability crisis had become. For Medicare beneficiaries and their families, the cap represents a hard-won victory and a meaningful step toward a healthcare system where a necessary medication is never financially out of reach.